U.S. Medical Equipment Stock News

LandBridge walked into this earnings season with a premium P/E and a reputation as a high margin, fee based infrastructure play. The stock had already climbed over the past quarter, yet the market still punched it 6.3% higher to about $80 after the Q2 print. That reaction reflects one headline: cash generation and profitability looked strong enough to keep the rich valuation intact. The single story investors are trading on today is margin quality. LandBridge reported record Q2 revenue of...

Qiagen stock barely flinched after earnings, slipping just 0.5% to about US$41.70 even after a quarter that quietly reset the profit story. The company delivered Q2 net sales of US$535 million, slightly above its own outlook, and adjusted earnings per share of US$0.62, also ahead of guidance. That kept the trailing net profit margin near 19%, a sharp contrast with the much thinner profitability investors saw a year ago. For anyone thinking beyond today’s small price move, the real question...

Zevra Therapeutics stock jumped 12.8% to US$11.88 in the first full session after its Q2 release, a sharp move for a company often framed as a long duration rare disease bet rather than a quarter-to-quarter story. The headline this time is profitability with cash to back it. Zevra reported US$39.7m in revenue and US$8.8m in net income, while lifting its cash, equivalents and investments to about US$260m. The gap between a single strong quarter and the longer term thesis is where the real work...

Symbotic stock just took a 15% hit in a single session, yet the earnings print reads more like a company finding its profit engine than one falling apart. Revenue landed at about US$721 million, close to the top of guidance, while adjusted earnings before interest, tax, depreciation and amortization more than doubled to US$95 million and cleared expectations. For a warehouse automation specialist that had only recently turned the earnings corner, that combination of strong top line and...

Aflac recently supported the United Way of the Chattahoochee Valley by providing a customized leadership development workshop, while analysts also highlighted that its second-quarter results were expected to benefit from growth in net earned premiums in the U.S. segment driven by higher sales. Beyond underscoring anticipated strength in its U.S. premium base, Aflac’s outreach shows how its internal leadership capabilities are being applied to strengthen community organizations. Next, we’ll...

U-Haul Holding stock barely flinched, up about 1.4% on the day, even as the headline told a more complicated story. Q1 FY2027 brought solid revenue of US$1.68b and a return to profit, with basic earnings per share of US$0.63 after recent quarterly losses. Yet net income of US$122.9m sat below last year’s US$142.3m, and investors had to weigh that softer profit against evidence that the core moving and storage engine is still pulling in more dollars. The market reaction looked calm; the...

Blue Bird just delivered one of the sharpest disconnects of this earnings season. The stock dropped 14.2% to about US$66 after the Q3 report, even though the company reported US$517.2m in revenue and basic earnings per share of US$5.41. That is a large increase from earlier in the fiscal year and leaves the trailing P/E near 7.4x compared with a much higher machinery industry average. Coming into the report, Blue Bird shares had already been under pressure over the last month. This quarter...

Howard Hughes Holdings stock jumped about 3.6% to around US$68 after the Q2 print, even though the shares are still down roughly 7.9% over the past month. The market is reacting to a headline quarter that combined a sharp revenue increase to about US$1.1b with a clear message. The real story was not a single-quarter beat or miss. It was management emphasizing a long-horizon plan that uses its real estate cash flows and a growing insurance platform to reshape how investors should think about...

Standard BioTools stock inched up about 3% to roughly US$0.80 after earnings, a small bounce that sits awkwardly against a longer slide of more than 20% over the past three months. The headline is not growth. It is the size and persistence of the losses. Q2 revenue came in around US$20.1m while the company reported a net loss from continuing operations over the past year of roughly US$53.9m. For anyone thinking beyond today’s tick higher, the key debate is whether that loss profile can...

Corpay stock barely flinched after earnings, up less than 1% to about $398, even as the company posted one of its cleanest quarters in recent memory. The market mood looks cautious while the numbers tell a stronger story. The headline is simple. Revenue reached about $1.34b and cash earnings per share hit a record $7 in the quarter. Management lifted full year cash EPS and revenue guidance. With the stock already up double digits over the past month, today’s muted move hints more at investors...

Duolingo just handed investors a sentiment test. The stock dropped about 9% today to US$122.58, even though the quarter featured solid revenue of US$298.454m and positive basic earnings per share of US$0.71. The market is reacting as if the growth story has cracked. The financials point to something more nuanced. Coming into this print, Duolingo had already cooled off in the short term, with shares down over the past week and month, while still positive over the past quarter. Today’s move is...

Arcutis Biotherapeutics slipped about 2.5% today to US$26.43, even though the company just turned in what many biotech investors look for most. The dermatology specialist posted Q2 net product revenue of US$129.9m and reported US$15m of net income. That short term pullback sits against a bigger picture of rising revenue guidance for 2026 and a stock that had gained roughly 25% over the past three months. The rest of this earnings breakdown focuses on how durable that profit turn and growth...

RxSight walked into this quarter with a stock that had been roughly flat over the past week and modestly higher over the past month. The immediate reaction told a different story. The share price slipped about 3% to US$6.08 after the Q2 release, as investors focused on pressure in the income statement rather than the long runway often associated with its light adjustable lens technology. The headline from these earnings is margin and loss pressure. Revenue for Q2 came in at US$33.7m while the...

Talen Energy stock came into this earnings day under pressure after a weak three month stretch, then jumped 2.6% to US$338.31 as investors absorbed a very different story from the income statement. The headline is simple: power generation and cash generation stole the show while reported earnings swung back into loss territory. Quarterly revenue landed at US$747 million and Talen Energy reported a net loss of US$92 million, yet the company highlighted strong adjusted earnings before interest,...

Energy Recovery stock barely flinched after earnings, slipping about 1.5%, yet the numbers tell a louder story than the price tape suggests. The headline is a sharp earnings reset. Q2 delivered a revenue haul of about US$12 million, while the company reported a loss of roughly US$3.2 million, a clear squeeze compared with its profit rich recent history. For a stock that had been treading water over the past month, the market now appears to be wrestling with one thing above all else:...

Traeger walked into this earnings print with the stock up over the past three months, yet the shares were hit hard today with a one-day drop of almost 13%. That indicates expectations had quietly crept higher. The headline from the quarter is not the top line. Revenue landed at about US$120 million, but the real story is a small adjusted profit on the income line alongside a reported net loss and an updated full-year revenue guide that now points lower. The market is voting on that tension in...

Akebia Therapeutics just took a 26% hit, with the stock sliding to about US$0.95, as investors reacted to a quarter that put its valuation strain back in the spotlight. The immediate trigger was Q2 revenue of US$49.1 million and another quarterly net loss. The key issue is what that means for a stock that trades on a very low price to sales ratio and a large gap to modelled future cash flow value. The short term looks painful on the screen. The bigger question is how long Akebia can run its...

Southwest Gas Holdings stock barely flinched after earnings, edging up about 2% to US$92.40, even though the headline story is about pressure on profitability rather than a blowout quarter. The shares had been trading at a rich 23.5x trailing P/E with strong trailing earnings momentum going into this report, so any hint of strain matters. The key issue this time is the squeeze between earnings power and the balance sheet. Management reaffirmed guidance and highlighted roughly US$1.25b of...

Herbalife shareholders woke up to a harsh verdict. The stock dropped about 9% to US$11.51 on the first trading day after earnings, even though the company delivered its fourth straight quarter of year on year sales growth and reported Q2 net sales of about US$1.3b. The real shock came on the bottom line. Herbalife swung from a profitable Q1 to a Q2 loss of US$26.3m as a refinancing related debt extinguishment charge hit earnings, even while adjusted EBITDA landed near the high end of...

Verra Mobility stock was already on a rough road over the past three months and today the brakes slammed harder as the share price fell 8.7% to US$5.12. The trigger was not a revenue miss. Quarterly revenue came in at US$263.6m and adjusted earnings per share reached US$0.38, while the headline number was a GAAP net loss of US$48.2m, driven largely by a non cash impairment in the Parking Solutions unit. The market is treating that loss as the whole story. The real question is whether that...

Figma stock just gave investors a hard reset, sliding about 15% today after a strong recent run. The immediate reaction is all about that price drop. The real story sits in the numbers. Q2 revenue reached about US$370m and net dollar retention of 136% underlines how existing customers keep spending more. Short term traders are fixated on the red screen. Long term holders will likely focus on a design and AI platform that just reported its third consecutive quarter of faster growth and now...

Tennant came into this print as a high P/E industrial stock with a premium reputation and a share price that had already been drifting down in recent months. The market did not wait for nuance. The stock dropped about 12% to US$76.90 after Q2 numbers showed that the real story this quarter was profit pressure, not demand. Revenue in Tennant’s floor cleaning equipment business held at US$324m, yet net income fell to US$7.6m and adjusted earnings per share slid to US$0.83. For a company priced...

Wix.com (NasdaqGS: WIX) and Thryv announced plans for a new partnership to combine AI-driven commerce, payments, and website tools for small and medium businesses. The agreement aims to connect Wix.com's platform with Thryv's existing customer base and direct sales force that focuses on service-based SMBs. Both companies plan to offer an integrated solution that brings together online booking, payments, websites, and automation under a single workflow. Investors are watching how this...

Beyond Meat stock dropped about 14% today, yet the latest quarter shows a company that just posted a profit and is trying to claw its way back from the edge. The disconnect is stark. You have a plant based meat pioneer trading around US$0.53 a share, with trailing earnings in the black and a P/E that screens as very low against food peers, yet the market continues to punish it. The headline this quarter is simple. Revenue of US$68.8m and positive earnings land against a backdrop of weak cash...